Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMETEO: T-VEC + Atezolizumab in Residual Breast Cancer
NCT03802604Phase 1Completed
- Sponsor
- SOLTI
- Start
- Dec 2018
- Primary completion
- Apr 2022
- Modality
- Oncolytic Viruses, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec and atezolizumab in breast cancer, sponsored by SOLTI. Primary endpoint: Rate of Residual Cancer Burden Class 0 and 1 at 24 months. Started Dec 2018; status: completed.
02
Drugs
talimogene laherparepvecatezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03802604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802604.